All In Biotech

Free tool

FAERS Monitor: Trulance

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 208745 or its brand name (Trulance, Plecanatide). Reports on generic versions are filed under their own applications.

Reports

2,075

Serious

758

37% of reports

Hospitalization

297

Death reported

77

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • diarrhoea405
  • nausea181
  • drug ineffective175
  • constipation174
  • abdominal distension120
  • fatigue119
  • abdominal pain113
  • abdominal pain upper108
  • headache108
  • dizziness102
  • pain102
  • product use in unapproved indication77
  • dyspnoea76
  • malaise75
  • vomiting75

Reports by year received

View as table
YearReports
20164
2017150
2018205
2019217
2020262
2021224
2022201
2023199
2024187
2025196
2026230

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,084 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
abdominal distensionSignal12011.79.81,164
constipationSignal1748.17.01,085
diarrhoeaSignal4056.45.81,882
abdominal pain upperSignal1085.34.4378
abdominal painSignal1134.94.1353
product use in unapproved indicationSignal773.12.5112
nauseaSignal1812.32.0140
dizzinessSignal1022.11.757
headache1081.71.535
malaise751.71.423
pain1021.71.428
vomiting751.61.317
fatigue1191.51.324
dyspnoea761.41.17
drug ineffective1751.31.216

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.